U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07145255) titled 'Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors' on Aug. 12.
Brief Summary: This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer Castration-resistant Prostate Cancer
Breast Cancer
Colo-rectal Cancer
Lung Cancer (Non-Small Cell)
Intervention:
DRUG: ADC
MBRC-201 ADC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: MBrace Therapeutics
Disclaimer: Curated by HT Syndication....